TITLE

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

AUTHOR(S)
Kellow, J.; Lee, O.Y.; Chang, F.Y.; Thongsawat, S.; Mazlam, M.Z.; Yuen, H.; Gwee, K.A.; Bak, Y.T.; Jones, J.; Wagner, A.
PUB. DATE
May 2003
SOURCE
Gut;May2003, Vol. 52 Issue 5, p671
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Tegaserod has been shown to be an effective therapy for the multiple symptoms of irritable bowel syndrome (lBS) in Western populations. However, little information is available regarding the use of tegaserod in the Asia-Pacific population. Aims: To evaluate the efficacy, safety, and tolerability of tegaserod versus placebo in patients with lBS from the Asia-Pacific region. Patients: A total of 520 patients from the Asia-Pacific region with lBS, excluding those with diarrhoea predominant lBS. Methods: Patients were randomised to receive either tegaserod 6 mg twice daily (n=259) or placebo (n=261) for a 12 week treatment period. The primary efficacy variable (over weeks 1-4) was the response to the question: "Over the past week do you consider that you have had satisfactory relief from your lBS symptoms?" Secondary efficacy variables assessed overall satisfactory relief over 12 weeks and individual symptoms of lBS. Results: The mean proportion of patients with overall satisfactory relief was greater in the tegaserod group than in the placebo group over weeks 1-4 (56% v 35%, respectively; p<0.0001) and weeks 1-12 (62% v44%, respectively; p<0.0001). A clinically relevant effect was observed as early as week 1 and was maintained throughout the treatment period. Reductions in the number of days with at least moderate abdominal pain/discomfort, bloating, no bowel movements, and hard/lumpy stools were greater in the tegaserod group compared with the placebo group. Headache was the most commonly reported adverse event (12.0% tegaserod v 11.1% placebo). Diarrhoea led to discontinuation in 2.3% of tegaserod patients. Serious adverse events were infrequent (1.5% tegaserod v 3.4% placebo). Conclusions: Tegaserod 6 mg twice daily is an effective, safe, and well tolerated treatment for patients in the Asia-Pacific region suffering from lBS and whose main bowel symptom is not diarrhoea.
ACCESSION #
9737017

 

Related Articles

  • Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Houghton, L.A.; Atkinson, W.; Whitaker, R.P.; Whorwell, P.J.; Rimmer, M.J. // Gut;May2003, Vol. 52 Issue 5, p663 

    Background: Meal ingestion is often associated with exacerbation of gastrointestinal symptoms in subjects with irritable bowel syndrome (lBS). Furthermore, recent preliminary data suggest that 5-hydroxytryptamine (5-HT) concentration in platelet poor plasma is elevated following meal ingestion...

  • Oesophageal motility in the irritable bowel syndrome. Whorwell, P.J.; Clouter, Carole; Smith, Colin L. // British Medical Journal (Clinical Research Edition);4/4/1981, Vol. 282 Issue 6270, p1101 

    Examines oesophageal motility to patients with irritable bowel syndrome. Importance of controls matched with age and sex; Features of patients with more than one abnormal pattern of motility; Symptoms of the disease.

  • Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study. Bonaz, B.; Baciu, M.; Papillon, E.; Bost, R.; Gueddah, N.; Le Bas, J.-F.; Fournet, J.; Segebarth, C. // American Journal of Gastroenterology;Mar2002, Vol. 97 Issue 3, p654 

    OBJECTIVES:In healthy subjects, the neural correlates of visceral pain bear much similarity with the correlates of somatic pain. In patients with irritable bowel syndrome, the central nervous system is believed to play a strong modulatory or etiological role in the pathophysiology of the...

  • Is there a difference between abdominal pain and discomfort in moderate to severe IBS patients? Sach, Joel; Bolus, Roger; Fitzgerald, Leah; Naliboff, Bruce D.; Chang, Lin; Mayer, Emeran A. // American Journal of Gastroenterology;Dec2002, Vol. 97 Issue 12, p3131 

    OBJECTIVES:The aims of this study were to: 1) determine the relative prevalence of self-reported pain-predominant and discomfort-predominant symptom patterns in irritable bowel syndrome (IBS) patients; and 2) test the hypotheses that pain-predominant patients report higher GI symptom severity,...

  • Quality of Life in Irritable Bowel Syndrome. Lea, R.; Whorwell, P.J. // PharmacoEconomics;Jun2001, Vol. 19 Issue 6, p643 

    Quality-of-life (QOL) assessment is becoming increasingly important in the evaluation of the impact of disease and the effect of therapy. This is particularly so for irritable bowel syndrome (IBS) where there is often a tendency for a chronic clinical course, but with no associated mortality....

  • Linzess for IBS, Constipation.  // Monthly Prescribing Reference;Oct2012, Vol. 28 Issue 10, pA-8 

    The article reports on the drug approval for Linzess, a linaclotide drug capsule that can be used for the treatment of chronic idiopathic constipation and constipation associated in irritable bowel syndrome (IBS-C) in adults.

  • Response to Rodrigo et al. Martinez, Cristina; Vicario, Maria; Santos, Javier // American Journal of Gastroenterology;Aug2014, Vol. 109 Issue 8, p1291 

    A letter to the editor is presented in response to the article in the previous issue about a study on molecular alterations in the tight junction signaling pathway in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

  • Response to Keszthelyi and Masclee. Wouters, M M; Balemans, D; Boeckxstaens, G E // American Journal of Gastroenterology;Aug2014, Vol. 109 Issue 8, p1286 

    A response to an article about the role of transient receptor potential vanilloid 1 (TRPV1) in the visceral hypersensitivity of irritable bowel syndrome (IBS) patients that was published in the previous issue is presented.

  • Comments on 'The Jejunum of Diarrhea-Predominant Irritable Bowel Syndrome Shows Molecular Alterations in the Tight Junction Signaling Pathway That Are Associated With Mucosal Pathobiology and Clinical Manifestations'. Rodrigo, Luis; Lauret, E; PĂ©rez, I; Suarez, A // American Journal of Gastroenterology;Aug2014, Vol. 109 Issue 8, p1290 

    A letter to the editor is presented in response to the article in the previous issue about the molecular alterations found at the level of the tight junctions in patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics